Mode
Text Size
Log in / Sign up
Phase 4 Completed N=153 Randomized Treatment

A Text Messaging Program for Smokers in Primary Care

Source: ClinicalTrials.gov NCT03174158 ↗
Enrolled (actual)
153
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Quit Attempts — 26; 33; 29; 31 Participants — p=0.07
◆ Published Evidence
Emerging
12citations · ~2 / year
Proactively Offered Text Messages and Mailed Nicotine Replacement Therapy for Smokers in Primary Care Practices: A Pilot Randomized Trial.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020 · Open access · Likely link

Summary

This study is a four arm pilot randomized controlled trial testing the effect of a 12 week text messaging intervention and a mailed nicotine medication intervention, alone and in combination to a control condition consisting of brief behavioral advice and usual care. Research Aim 1: To test, in a 4 arm pilot randomized controlled trial (N=50/group), the effect of a text messaging program and mailed nicotine replacement therapy on smoking outcomes and medication use. Hypothesis 1: A text messaging intervention will increase the proportion of smokers making a quit attempt compared to smokers receiving no text messaging. Hypothesis 2: A text messaging intervention will increase adherence to nicotine replacement therapy compared to subjects receiving only 2 weeks of nicotine replacement therapy. Hypothesis 3: A text messaging intervention will increase the rate of biochemically confirmed past 7-day point prevalent tobacco abstinence at end of treatment compared to subjects receiving no text messaging intervention. Hypothesis 4: A text messaging intervention will increase the number of days not smoking compared to subjects receiving no text messaging intervention. Hypothesis 5: A text messaging intervention will decrease the number of cigarettes smoked per day compared to subjects receiving no text messaging intervention.

Linked Publications (2)

  • Proactively Offered Text Messages and Mailed Nicotine Replacement Therapy for Smokers in Primary Care Practices: A Pilot Randomized Trial.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020 · 12 citations · Open access · Likely link
  • Proactive text messaging (GetReady2Quit) and nicotine replacement therapy to promote smoking cessation among smokers in primary care: A pilot randomized trial protocol.
    Contemporary clinical trials · 2019 · 10 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Quit Attempts
26; 33; 29; 31 0.07
SECONDARY
7 Day Point Prevalent Abstinence
4; 10; 10; 9
SECONDARY
7 Day Point Prevalent Abstinence
4; 10; 10; 9
SECONDARY
Milligrams of Nicotine Medication Used
84.2; 58.0
SECONDARY
Percentage of Days Not Smoked
23.7; 37.2; 29.0; 36.1
SECONDARY
Exhaled Carbon Monoxide
1; 3; 3; 2
SECONDARY
Days Nicotine Medication Used
5.3; 3.3
SECONDARY
Milligrams Nicotine Medication Used
33.8; 22.3
SECONDARY
Change in Cigarettes Per Day
-9.3; -8.6; -11.3; -8.9

Eligibility Criteria

Inclusion Criteria

  • Adults (≥18 years)
  • Smoking status of current smoker in structured field of electronic health record (EHR)
  • Language listed as English in EHR
  • Massachusetts General Hospital patient, Partners healthcare primary care provider (PCP)
  • PCP visit in the past 2 years
  • Mobile telephone number listed in EHR

Exclusion Criteria

  • Not a current daily smoker defined as not having smoked ≥100 cigarettes in lifetime or self-report of less than daily current smoking
  • Pregnant, planning to become pregnant in the next 3 months, or breastfeeding.
  • Past 30-day use of nicotine replacement therapy, bupropion, or varenicline.
  • Past 30-day use of Massachusetts state quit-line, "QuitWorks" or SmokefreeTXT programs
  • Prior serious adverse reaction to the nicotine patch or lozenge defined as any reaction that was life-threatening, required hospitalization, or other clinical evaluation
  • Ever had an allergy to nicotine patch
  • Weight < 100 pounds
  • Unstable coronary disease
  • Unstable arrhythmia
  • Dementia or active psychosis or schizoaffective disorder affecting ability to consent
  • Willing and able to receive and participate with a text message program for up to 12 weeks
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03174158) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search